News & Updates

In patients with primary hyperparathyroidism (PHPT), parathyroidectomy significantly reduces the risk of major adverse cardiovascular events (MACE), a population-wide target trial emulation (TTE) study in Hong Kong has shown.

Orforglipron has demonstrated cardiovascular (CV) safety in adults with type 2 diabetes (T2D) and obesity or overweight who are at high cardio-renal risk, as shown in the phase III ACHIEVE-4 study.

The risk of neovascular age-related macular degeneration (NVAMD) associated with the use of semaglutide is similar to that with other glucagon-like peptide-1 receptor agonists (GLP-1 RAs) or non-GLP-1 RAs among adults with type 2 diabetes (T2D), suggests a study.

Healthy premenopausal women with overweight who lose weight through diet with or without aerobic or resistance exercise show a significant reduction in the risks of major adverse cardiovascular events (MACE) and type 2 diabetes (T2D). However, such risks have rebounded with weight regain.

Approximately 40 percent of individuals who received screening through the Chronic Disease Co-Care (CDCC) Pilot Scheme were found to have diabetes mellitus (DM), hypertension (HTN) or prediabetes. Their cardiometabolic outcomes improved following multidisciplinary management.

Depression is associated with greater risks of incident cardiovascular disease (CVD) and all-cause mortality in patients with type 2 diabetes (T2D), a population-based mediation analysis of 0.5 million Chinese people has shown.